Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02677896
Registration number
NCT02677896
Ethics application status
Date submitted
5/02/2016
Date registered
9/02/2016
Titles & IDs
Public title
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Query!
Scientific title
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Query!
Secondary ID [1]
0
0
2015-003869-28
Query!
Secondary ID [2]
0
0
9785-CL-0335
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ARCHES
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Hormone Sensitive Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Allergies
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Enzalutamide
Treatment: Drugs - Placebo
Experimental: Enzalutamide + Androgen Deprivation Therapy (ADT) - Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
Placebo comparator: Placebo + Androgen Deprivation Therapy (ADT) - Participants received matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
Experimental: Placebo followed by Enzalutamide - Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
Treatment: Drugs: Enzalutamide
Oral
Treatment: Drugs: Placebo
Oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria
Query!
Assessment method [1]
0
0
rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline or week 13 according to PCWG2 criteria, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.
Query!
Timepoint [1]
0
0
From randomization until the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Primary outcome [2]
0
0
rPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria
Query!
Assessment method [2]
0
0
rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline for week 13 or the best response on treatment for week 25 or later assessments, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.
Query!
Timepoint [2]
0
0
From randomization until the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months.
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to death due to any cause. In participants still alive at the date of the analysis cutoff point, OS was censored on the last date the participant was known to be alive. OS was analyzed using Kaplan-Meier estimates.
Query!
Timepoint [1]
0
0
From date of randomization to OS final analysis (28 May 2021); Maximum treatment duration was 58.6 months
Query!
Secondary outcome [2]
0
0
Time to Prostate Specific Antigen (PSA) Progression
Query!
Assessment method [2]
0
0
Time to PSA progression was calculated as the time from the date of randomization to the first observation of PSA progression. A PSA progression was defined as a = 25% increase and an absolute increase of = 2 ng/mL above the nadir, which was confirmed by a second consecutive value at least 3 weeks later. In participants with no PSA progression, time to PSA progression was censored on the date of the last PSA sample taken (or last value prior to 2 or more consecutive missed PSA assessments).
Query!
Timepoint [2]
0
0
From randomization until the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [3]
0
0
Time to Start of New Antineoplastic Therapy
Query!
Assessment method [3]
0
0
In participants with a new antineoplastic therapy initiated for prostate cancer after randomization, time to start of a new antineoplastic therapy was defined as the time interval from randomization to the date of the first dose administration of the first antineoplastic therapy. In participants with no new antineoplastic therapy initiated for prostate cancer after randomization, time to start of new antineoplastic therapy was censored on the last visit date or the date of randomization, whichever occurred last. Time to start of new antineoplastic therapy was analyzed using Kaplan-Meier estimates.
Query!
Timepoint [3]
0
0
From date of randomization to data cut-off date (28 May 2021); Maximum treatment duration was 58.6 months
Query!
Secondary outcome [4]
0
0
PSA Undetectable Rate
Query!
Assessment method [4]
0
0
The PSA undetectable rate was defined as the percentage of participants with undetectable (\< 0.2 ng/mL) PSA values at any time during study treatment, of those participants with detectable (= 0.2 ng/mL) PSA values at baseline.
Query!
Timepoint [4]
0
0
Up to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [5]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [5]
0
0
The ORR was calculated as the percentage of participants who achieved a completed response (CR) or a partial response (PR) (unconfirmed responses) in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by ICR.
Query!
Timepoint [5]
0
0
Up to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [6]
0
0
Time to Deterioration in Urinary Symptoms
Query!
Assessment method [6]
0
0
In participants with deterioration, the time to deterioration was calculated as the time interval between randomization and the first deterioration in urinary symptoms at any postbaseline visit. A deterioration in urinary symptoms was defined as an increase in the Quality of Life Prostate-specific Questionnaire (QLQ-PR25) modified urinary symptoms. Subscale score by = 50% of the standard deviation observed in the QLQ-PR25 modified urinary symptoms subscale score at baseline. Modified urinary symptoms subscale score consisted of 3-items (Q31 - Q33) from the QLQ-PR25, each scored from 1 (not at all) to 4 (very much). The total modified urinary symptoms subscale score ranges from 0-100, with higher scores represents a higher level of symptomatology/problems. In participants without deterioration in urinary symptoms, the time to deterioration in urinary symptoms was censored on the date the last urinary symptoms QLQ-PR25 score was calculable.
Query!
Timepoint [6]
0
0
From randomization to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [7]
0
0
Time to First Symptomatic Skeletal Event (SSE)
Query!
Assessment method [7]
0
0
Time to first SSE was calculated as the time from randomization to the occurrence of the first SSE prior to the data analysis cut-off date. An SSE was defined as radiation to bone, surgery to bone, clinically apparent pathological bone fracture, or spinal cord compression. In participants with no SSE by the time of the data cut-off point, time to SSE was censored on the last visit date or the date of randomization, whichever occurred last.
Query!
Timepoint [7]
0
0
From randomization to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [8]
0
0
Time to Castration Resistance
Query!
Assessment method [8]
0
0
Time to castration resistance was calculated as the time from randomization to the first castration-resistant event. A castration resistance event was defined as any of the following in the presence of castrate levels of testosterone (\< 50 ng/dL): radiographic disease progression, PSA progression or SSE, whichever occurred first. In participants with no documented castration resistance event, the time to castration resistance was censored on the latest date from: the date of last radiologic assessment, the last PSA sample taken prior to the start of any new prostate cancer therapy and prior to 2 or more consecutive missed PSA assessments (if applicable), and the last visit date performed.
Query!
Timepoint [8]
0
0
From randomization to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [9]
0
0
Time to Deterioration of Quality of Life (QoL) in Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Query!
Assessment method [9]
0
0
Time to deterioration of QoL was calculated as the time interval from the date of randomization to the first date a decline from baseline of 10 points or more in the FACT-P total score was recorded. The FACT-P consists of 27 core items that assess participant function in 4 domains and 12 prostate cancer-related items grouped into 5 subscales as follows: physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and prostate cancer subscale. Each item is rated on a 0 to 4 Likert-type scale. The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0 to 156), where high score represent better quality of life. In participants without FACT-P progression, the time to deterioration of QoL was censored on the date of the last FACT-P total score was calculable.
Query!
Timepoint [9]
0
0
From randomization to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Secondary outcome [10]
0
0
Time to Pain Progression Based on Brief Pain Inventory-Short Form (BPI-SF)
Query!
Assessment method [10]
0
0
Time to pain progression was defined as time from randomization to the first pain progression event. Pain progression was defined as an increase of = 30% from baseline in the average BPI-SF pain severity score. BPI-SF contains 9 questions with rating scales from 0 (no pain/no interference) to 10 (worst pain/interferes completely). Total score was calculated as the average of each question. Higher scores represent a higher level of pain or interference. In participants with no pain progression event, time to pain progression was censored on the last visit date where BPI-SF was collected.
Query!
Timepoint [10]
0
0
From randomization to the data cut-off date of 14 October 2018; maximum duration of treatment was 26.6 months
Query!
Eligibility
Key inclusion criteria
* Subject is considered an adult according to local regulation at the time of signing informed consent.
* Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
* Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
* Once randomized at day 1, subject must maintain ADT with an LHRH agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).
* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Inclusion Criteria for Open-Label Extension:
* Subject received randomized double-blind treatment in ARCHES
* Subject has not met any of the discontinuation criteria in the main ARCHES protocol
* Subject is willing to maintain ADT with LHRH agonist or antagonist or has had a bilateral orchiectomy.
* Subject is able to swallow enzalutamide capsules whole and to comply with study requirements throughout the study
* Subject and subject's female partner agree to follow contraception and sperm donation requirements in main protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subject has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (the following exceptions are permitted):
* Up to 3 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1, with no radiographic evidence of disease progression or rising PSA levels prior to day 1;
* Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1;
* Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of day 1 and no evidence of disease progression during or after the completion of docetaxel therapy;
* Up to 6 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to day 1;
* Prior ADT given for < 39 months in duration and > 9 months before randomization as neoadjuvant/adjuvant therapy.
* Subject had a major surgery within 4 weeks prior to day 1.
* Subject received treatment with 5-a reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.
* Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.
* Subject received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.
* Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.
* Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an investigational agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).
* Subject has known or suspected brain metastasis or active leptomeningeal disease.
* Subject has absolute neutrophil count < 1500/µL, platelet count < 100000/µL or hemoglobin < 10 g/dL (6.2 mmol/L).
* Subject has total bilirubin (TBL) = 1.5 x the upper limit of normal (ULN) (except subjects with documented Gilbert's disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 x the ULN .
* Subject has creatinine > 2 mg/dL (177 µmol/L).
* Subject has albumin < 3.0 g/dL (30 g/L).
* Subject has a history of seizure or any condition that may predispose to seizure.
* Subject has history of loss of consciousness or transient ischemic attack within 12 months prior to day 1.
* Subject has clinically significant cardiovascular disease.
* Subject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosis
Exclusion Criteria for Open-Label Extension:
* Subject has taken commercially available enzalutamide (Xtandi).
* Subject's disease has progressed radiographically during the double-blind period of the study and treatment with study drug was stopped prior to study-wide unblinding. (Note: Subjects who progressed radiographically while in the double-blind portion of the study and continued treatment per protocol are allowed to participate in the open label extension.)
* After study-wide unblinding, subject has started any new investigational agent or anti-neoplastic therapy intended to treat prostate cancer
* Subject has any clinically significant disorder or condition including excessive alcohol or drug abuse, or secondary malignancy, which may interfere with study participation
* Subject has current or previously treated brain metastasis or active leptomeningeal disease
* Subject has a history of seizure or any condition that may increase the risk of seizure
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/03/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/07/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1150
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Site AU61016 - Camperdown
Query!
Recruitment hospital [2]
0
0
Site AU61007 - St Leonards
Query!
Recruitment hospital [3]
0
0
Site AU61006 - Sydney
Query!
Recruitment hospital [4]
0
0
Site AU61009 - Tweed Heads
Query!
Recruitment hospital [5]
0
0
Site AU61013 - Waratah
Query!
Recruitment hospital [6]
0
0
Site AU61001 - Woodville South
Query!
Recruitment hospital [7]
0
0
Site AU61004 - Ballarat
Query!
Recruitment hospital [8]
0
0
Site AU61015 - Clayton
Query!
Recruitment hospital [9]
0
0
Site AU61017 - Parkville
Query!
Recruitment hospital [10]
0
0
Site AU61008 - St. Albans
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
- Sydney
Query!
Recruitment postcode(s) [4]
0
0
2485 - Tweed Heads
Query!
Recruitment postcode(s) [5]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [6]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [7]
0
0
- Ballarat
Query!
Recruitment postcode(s) [8]
0
0
- Clayton
Query!
Recruitment postcode(s) [9]
0
0
- Parkville
Query!
Recruitment postcode(s) [10]
0
0
- St. Albans
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Santa Fe
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Tucuman
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Hainaut
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Oost-Vlaanderen
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
West-Vlaanderen
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liege
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Yvoir
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Alberta
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
British Columbia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
IX Region
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
RM
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Santiago
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Valparaiso
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Viña Del Mar
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Hovestaden
Query!
Country [42]
0
0
Denmark
Query!
State/province [42]
0
0
Midtjylland
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Nordjylland
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Herlev
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Odense C
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Etelä-Suomen Lääni
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Länsi-Suomen Lääni
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
Oulun Laani
Query!
Country [49]
0
0
Finland
Query!
State/province [49]
0
0
Oulu
Query!
Country [50]
0
0
Finland
Query!
State/province [50]
0
0
Pietarsaari
Query!
Country [51]
0
0
Finland
Query!
State/province [51]
0
0
Turku
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Maine-et-Loire
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Val-de-Marne
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Bordeaux
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Caen Cedex 05
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
La Roche sur Yon
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Le Mans Cedex 2
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Lille Cedex
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Lyon Cedex 3
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Nimes
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Pierre Benite
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Quimper
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Saint Mande
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Baden-Württemberg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Bonn
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Hamburg
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Heidelberg
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
HaMerkaz
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Beer-Sheva
Query!
Country [70]
0
0
Israel
Query!
State/province [70]
0
0
Haifa
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Jerusalem
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Emilia-Romagna
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Lombardia
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Piemonte
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Toscana
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Trentino-Alto Adige
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Veneto
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Candiolo
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Chiba
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Gunma
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Kagawa
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Kanagawa
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Miyagi
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Osaka
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Tokyo
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Yamaguchi
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Fukuoka
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Kyoto
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Nagasaki
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Niigata
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Yamagata
Query!
Country [92]
0
0
Korea, Republic of
Query!
State/province [92]
0
0
Gyeonggi-do
Query!
Country [93]
0
0
Korea, Republic of
Query!
State/province [93]
0
0
Busan
Query!
Country [94]
0
0
Korea, Republic of
Query!
State/province [94]
0
0
Incheon
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Seoul
Query!
Country [96]
0
0
Netherlands
Query!
State/province [96]
0
0
Friesland
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Gelderland
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Noord-Brabant
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Noord-Holland
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Overijssel
Query!
Country [101]
0
0
Netherlands
Query!
State/province [101]
0
0
Zuid-Holland
Query!
Country [102]
0
0
New Zealand
Query!
State/province [102]
0
0
Bay Of Plenty
Query!
Country [103]
0
0
New Zealand
Query!
State/province [103]
0
0
Northland
Query!
Country [104]
0
0
New Zealand
Query!
State/province [104]
0
0
South Island
Query!
Country [105]
0
0
New Zealand
Query!
State/province [105]
0
0
Tasman District
Query!
Country [106]
0
0
New Zealand
Query!
State/province [106]
0
0
Hamilton
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Dolnoslaskie
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Malopolskie
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Mazowieckie
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Pomerania
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Pomorskie
Query!
Country [112]
0
0
Poland
Query!
State/province [112]
0
0
Myslowice
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Cluj
Query!
Country [114]
0
0
Romania
Query!
State/province [114]
0
0
Timis
Query!
Country [115]
0
0
Romania
Query!
State/province [115]
0
0
Brasov
Query!
Country [116]
0
0
Romania
Query!
State/province [116]
0
0
Bucharest
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Ivanovo
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Moscow
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Omsk
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Penza
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
St. Petersburg
Query!
Country [122]
0
0
Slovakia
Query!
State/province [122]
0
0
Bratislava
Query!
Country [123]
0
0
Slovakia
Query!
State/province [123]
0
0
Kosice
Query!
Country [124]
0
0
Slovakia
Query!
State/province [124]
0
0
Michalovce
Query!
Country [125]
0
0
Slovakia
Query!
State/province [125]
0
0
Nitra
Query!
Country [126]
0
0
Slovakia
Query!
State/province [126]
0
0
Poprad
Query!
Country [127]
0
0
Slovakia
Query!
State/province [127]
0
0
Trencin
Query!
Country [128]
0
0
Slovakia
Query!
State/province [128]
0
0
Žilina
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
A Coruña
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Asturias
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Barcelona
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Cataluña
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Comunidad Valenciana
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Navarra
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Avila
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Madrid
Query!
Country [137]
0
0
Sweden
Query!
State/province [137]
0
0
Orebro Län
Query!
Country [138]
0
0
Sweden
Query!
State/province [138]
0
0
Skåne Län
Query!
Country [139]
0
0
Sweden
Query!
State/province [139]
0
0
Sodermanlands Lan
Query!
Country [140]
0
0
Sweden
Query!
State/province [140]
0
0
Vasternorrlands Lan
Query!
Country [141]
0
0
Sweden
Query!
State/province [141]
0
0
Vastra Gotalands Lan
Query!
Country [142]
0
0
Taiwan
Query!
State/province [142]
0
0
Kaohsiung
Query!
Country [143]
0
0
Taiwan
Query!
State/province [143]
0
0
Taichung
Query!
Country [144]
0
0
Taiwan
Query!
State/province [144]
0
0
Taipei
Query!
Country [145]
0
0
Taiwan
Query!
State/province [145]
0
0
Taoyuan
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Astellas Pharma Global Development, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02677896
Query!
Trial related presentations / publications
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 Oct;78(4):603-614. doi: 10.1016/j.eururo.2020.03.019. Epub 2020 Apr 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Astellas Pharma Global Development, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Query!
Available to whom?
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.clinicalstudydatarequest.com/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/96/NCT02677896/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/96/NCT02677896/SAP_001.pdf
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeie...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT02677896